Original Article

Proportion and Characterization of Co-infections of HIV and Hepatitis C or Hepatitis B among People with HIV in Alabama, 2007–2016

Authors: Charlene Siza, DVM, MPH, Danae Bixler, MD, MPH, Sherri Davidson, PhD, MPH


Objectives: People living with human immunodeficiency virus (HIV) have an increased risk of other infections, including viral hepatitis, which can complicate the treatment and progression of the disease. We sought to characterize Alabama cases of HIV co-infected with hepatitis C virus or hepatitis B virus.

Methods: Using surveillance data, we defined co-infection as a person identified as having hepatitis C or hepatitis B and HIV during 2007−2016. We compared demographics, outcomes, and risk factors for co-infected versus monoinfected individuals with HIV. We mapped co-infected individuals’ distribution.

Results: Of 5824 people with HIV, 259 (4.4%) were co-infected with hepatitis C (antibody or RNA positive) and 145 (2.5%) with hepatitis B (surface antigen, e antigen, or DNA positive) during 2007–2016. Individuals with HIV and hepatitis C had a greater odds of injection drug use (adjusted odds ratio 9.7; 95% confidence interval 6.0–15.5). Individuals with HIV and hepatitis B had a greater odds of male-to-male sexual contact (adjusted odds ratio 1.7; 95% confidence interval 1.1–2.6). Co-infection was greater in urban public health districts.

Conclusions: We identified risk behaviors among Alabama populations associated with increased odds for HIV and viral hepatitis co-infection. Outreach, prevention, testing, and treatment resources can be targeted to these populations.
Posted in: Infectious Disease55 Acquired Immunodeficiency Syndrome (AIDS) And Human Immunodeficiency Virus (HIV) Infection7

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Andreoni M, Giacometti A, Maida I, et al. HIV-HCV co- infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci 2012;16:1473-1483.
2. Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS 2016;11:521-526.
3. Verucchi G, Calza L, Manfredi R, et al. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004;32:33-46.
4. Bosh KA, Coyle JR, Hansen V, et al. HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities. Epidemiol Infect 2018;146:920-930.
5. Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS 2011;6:451-458.
6. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009;23:F1-F7. doi: 10.1097/QAD.0b013e32832e5631.
7. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 2016;20:607-628.
8. Abara WE, Qaseem A, Schillie S, et al. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2017;167:794-804.
9. Thornton AC, Jose S, Bhagani S, et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS 2017;31:2525-2532.
10. Prussing C, Chan C, Pinchoff J, et al. HIV and viral hepatitis co-infection in New York City, 2000-2010: prevalence and case characteristics. Epidemiol Infect 2015;143:1408-1416.
11. Speers S, Klevens RM, Vonderwahl C, et al. Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states. Public Health Rep 2011;126:344-348.
12. Chun HM, Fieberg AM, Hullsiek KH, et al. The epidemiology of hepatitis B virus infection in a U.S. cohort of HIV-infected individuals during the last 20 years. Clin Infect Dis 2010;50:426-436.
13. Butt ZA, Wilkins MJ, Hamilton E, et al. Hepatitis B and C co-infection in HIV/AIDS population in the state of Michigan. Epidemiol Infect 2013;141:2604-2611.
14. Alabama State Board of Health, Alabama Department of Public Health, Division of Disease Control. Notifiable diseases. https://www.alabamapublichealth.gov/publications/assets/notifiablediseases.pdf. Updated August 4, 2018. Accessed September 30, 2019.
15. Fellegi IP, Sunter AB. A theory for record linkage. J Am Stat Assoc 1969;64:1183.
16. Centers for Disease Control and Prevention, National Notifiable Diseases Surveillance System. Surveillance case definitions for current and historical conditions. https://wwwn.cdc.gov/nndss/conditions. Published August 2, 2017. Accessed November 3, 2017.
17. Ham DC, Huang Y, Gvetadze R, et al. Health care use and HIV testing of males aged 15-39 years in physicians’ offices-United States, 2009-2012. MMWR Morb Mortal Wkly Rep 2016;65:619-622.
18. Wejnert C, Hess KL, Hall HI, et al. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs-United States. MMWR Morb Mortal Wkly Rep 2016;65:1336-1342.
19. Singh S, Hu X, Wheeler W, et al. HIV diagnoses among men who have sex with men and women-United States and 6 dependent areas, 2008-2011. Am J Public Health 2014;104:1700-1706.
20. Reif S, Safley D, McAllaster C, et al. State of HIV in the US Deep South. J Community Health 2017;42:844-853.
21. Prejean J, Tang T, Hall HI. HIV diagnoses and prevalence in the southern region of the United States, 2007-2010. J Community Health 2013;38:414-426.
22. Tedaldi EM, Hullsiek KH, Malvestutto CD, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 2003;36:1313-1317.
23. Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis 2013;26:66-72.
24. Hagan H, Jordan AE, Neurer J, et al. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 2015;29:2335-2345.
25. Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection-an update. Microb Cell 2016;3:420-437.
26. Kahn J. Preventing hepatitis A and hepatitis B virus infections among men who have sex with men. Clin Infect Dis 2002;35:1382-1387.
27. Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database System Rev 2017;9:CD012021.
28. Canary L, Hariri S, Campbell C, et al. Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States. Clin Infect Dis 2017;65:514-517.
29. Sharp A, Jones A, Sherwood J, et al. Impact of Medicaid expansion on access to opioid analgesic medications and medication-assisted treatment. Am J Public Health 2018;108:642-648.
30. Onofrey S, Aneja J, Haney GA, et al. Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review. Ann Intern Med 2015;163:254-261.
31. Zhou Y-H, Yao Z-H, Liu F-L, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan Province, China. PLoS One 2012;7:e42937.